RESUMEN
Misuse of chloramphenicol (CAP) can lead to severe food safety issues. Therefore, the accurate and sensitive detection of CAP residues is important for public health. Herein, a convenient and reliable interfacial self-assembly technique was used to form a uniform Au@Ag nanobipyramids (NBPs) film on an ordered SiO2 nanosphere array (SiO2 NS), which served as a Raman-enhanced substrate. In conjunction with a deoxyribonucleic acid enzyme-induced signal amplification strategy, we developed a novel surface-enhanced Raman scattering (SERS) biosensor for the selective and sensitive detection of CAP. The biosensor exhibited a detection limit of 6.42 × 10-13 mol·L-1 and a detection range of 1.0 × 10-12-1.0 × 10-6 mol·L-1. The biosensor could detect CAP in spiked milk samples with a high accuracy, and its recovery rates ranged from 97.88% to 107.86%. The as-developed biosensor with the advantages of high sensitivity and high selectivity offers a new strategy for the rapid, reliable and sensitive detection of CAP, rendering it applicable to food safety control.
Asunto(s)
Técnicas Biosensibles , Cloranfenicol , ADN Catalítico , Contaminación de Alimentos , Oro , Límite de Detección , Leche , Dióxido de Silicio , Plata , Espectrometría Raman , Dióxido de Silicio/química , Cloranfenicol/análisis , Oro/química , Técnicas Biosensibles/instrumentación , Técnicas Biosensibles/métodos , Plata/química , Espectrometría Raman/métodos , Espectrometría Raman/instrumentación , Contaminación de Alimentos/análisis , Leche/química , ADN Catalítico/química , Animales , Nanopartículas del Metal/química , Antibacterianos/análisisRESUMEN
Chloramphenicol (CAP) residue in food can cause great harm to human health, it is important to develop a rapid and sensitive method to detect CAP. Here, molecularly imprinted polymer (MIP) was combined with metal-organic frameworks@Au (MOFs@Au) collaborative construction surface-enhanced Raman spectroscopy (SERS) based aptasensor for CAP ultrasensitive detection. MOFs@Au first carried the Raman signal molecule toluidine blue (TB) and aptamer to form MOFs@Au@TB@Apt. In addition, rMIP (CAP was removed) was dropped onto the uniform three-dimensional (3D) SERS substrate SiO2@AuAg to form SiO2@AuAg@rMIP. In the presence of target CAP, it could be specifically captured with rMIP by covalent interaction and was recognised by the aptamer. During this time, SiO2@AuAg@rMIP@CAP could selectively connect MOFs@Au@TB@Apt to realise synergistic enhance the Raman signal. Based on this principle, the proposed SERS aptasensor exhibits excellent sensitivity with a detection limit of 7.59×10-13 M for CAP, providing a new strategy for trace detection in food.
Asunto(s)
Técnicas Biosensibles , Nanopartículas del Metal , Estructuras Metalorgánicas , Humanos , Cloranfenicol , Dióxido de Silicio/química , Oro/química , Técnicas Biosensibles/métodos , Espectrometría Raman/métodos , Oligonucleótidos , Nanopartículas del Metal/química , Límite de DetecciónRESUMEN
Biomimetic inorganic nanoenzyme is a kind of nanomaterial with long-term stability, easy preparation and low cost, which could instead of natural biological enzyme. Metal-organic framework (MOFs) as effectively nanoenzyme was attracted more attention for the adjustability and large specific surface area. This design is based on the catalase-like catalytic activity of 2D metal-organic frameworks (MOFs) and the high sensitivity of surface enhanced Raman spectroscopy (SERS) biosensors to construct a novel SERS biosensor capable of efficiently detecting mercury (Hg2+). In this study, 2D MOFs nanozyme was instead of 3D structure with more effecient catalytic site, which can catalyze o-Phenylenediamine (OPD) to OPDox with the assistance of H2O2. Besides, a magnetic composite nanomaterial Fe3O4@Ag@OPD was prepared as a signal carrier. In the presence of Hg2+, T-Hg2+-T base pairs were used to connect the two materials to realize Raman signal change. Based on this principle, the SERS sensor can realize the sensitive detection of Hg2+, the detection range is 1.0 × 10-12 â¼ 1.0 × 10-2 molâ§L-1, and the detection limit is 1.36 × 10-13 molâ§L-1. This method greatly improves the reliability of SERS sensor for detecting the target, and provides a new idea for detecting metal ions in the environment.
Asunto(s)
Mercurio , Nanopartículas del Metal , Estructuras Metalorgánicas , Fenilendiaminas , Estructuras Metalorgánicas/química , Peróxido de Hidrógeno , Reproducibilidad de los Resultados , Espectrometría Raman/métodos , Fenómenos Magnéticos , Nanopartículas del Metal/químicaRESUMEN
Background: Radiofrequency ablation (RFA) and chemotherapy are used to treat lung cancer or pulmonary metastases, but no direct comparison of overall survival (OS) has been published. The present study aimed to assess the OS of RFA and/or chemotherapy in patients with lung cancer or pulmonary metastases who were not candidates for surgical resection. Methods: To identify relevant studies, the following databases were electronically searched from their inception to 31 March 2023: PubMed, Embase, Web of Science, Cochrane Library, Scopus, Ovid, ScienceDirect, SinoMed, China National Knowledge Infrastructure Database, Chongqing VIP Chinese Science and Technology Periodical Database, Wanfang Database, LILACS, ClinicalTrials.gov, and Chictr.org. Manual retrieval was also conducted. We used published hazard ratios (HRs) if available or estimates from other survival data. Results: A total of 1,387 participants from 14 trials were included in the final analysis. Patients treated with RFA combined with chemotherapy significantly improved OS compared with those treated with chemotherapy alone [HR 0.50, 95% confidence interval (CI) 0.41-0.61; p < 0.00001], with an absolute difference at 12 months of 29.6% (95% CI 23.7-35.5), at 24 months of 19.2% (95% CI 10.1-28.2), and at 36 months of 22.9% (95% CI 12.0-33.7). No statistically significant difference was observed in the subgroups of case type, cancer type, chemotherapy drugs, and tumor size. The HR for OS with RFA plus chemotherapy vs. RFA alone was 0.53 (95% CI 0.41-0.70; p < 0.00001), corresponding to a 27.1% (95% CI 18.3-35.8), 31.0% (95% CI 19.9-41.9), and 24.9% (95% CI 15.0-34.7) absolute difference in survival at 12 months, 24 months, and 36 months, respectively. Subgroup analysis by geographic region and TNM stage showed that RFA combined with chemotherapy still significantly improved OS compared to RFA. The HR of RFA vs. chemotherapy was 0.98 (95% CI 0.60-1.60; p = 0.94), with an absolute difference at 12 months of 1.4% (95% CI -19.2 to 22.1), at 24 months of 7.8% (95% CI -11.3 to 26.8), and at 36 months of 0.3% (95% CI -13.2 to 13.8). The overall indirect comparison of OS for RFA vs. chemotherapy was 0.95 (95% CI 0.72-1.26; p = 0.74). Data on progression-free survival were not sufficiently reported. Conclusion: RFA combined with chemotherapy might be a better treatment option for patients with lung cancer or pulmonary metastases than chemotherapy alone or RFA alone. The comparison between RFA and/or chemotherapy remains to be specifically tested. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=335032, identifier CRD42022335032.
Asunto(s)
Ablación por Catéter , Neoplasias Pulmonares , Ablación por Radiofrecuencia , Humanos , Resultado del Tratamiento , Neoplasias Pulmonares/etiología , Modelos de Riesgos ProporcionalesRESUMEN
RATIONALE: Congenital dysfibrinogenemia (CD) is a rare coagulation system disease that is often treated without unified management. Individualized treatment thereof presents clinicians with great challenges. PATIENT CONCERNS: A patient who was about to undergo total knee arthroplasty was found to have CD. DIAGNOSES: Coagulation screening revealed low fibrinogen, prolonged thrombin time, minor prolonged prothrombin time, and normal activated partial thromboplastin time were detected during admission, but no abnormal personal and family history findings were observed. Therefore, CD and hypofibrinogenemia were suspected. The gene sequencing confirmed the diagnosis of CD. INTERVENTIONS: The patient received plenty and low level of fibrinogen concentrate during 2 perioperative periods, respectively. OUTCOMES: Successful clinical outcomes were obtained using different treatment strategies. LESSONS: In contrast to prior case reports, this case illustrates the feasibility of low dosing of fibrinogen supplements within an asymptomatic patient in a selective operation. Changes in the level of fibrinogen and fibrin degradation product are of great importance for individualized treatment after supplementation.
Asunto(s)
Afibrinogenemia , Artroplastia de Reemplazo de Rodilla , Trastornos de la Coagulación Sanguínea , Hemostáticos , Humanos , Masculino , Afibrinogenemia/genética , Fibrinógeno/uso terapéutico , Fibrinógeno/genética , Trastornos de la Coagulación Sanguínea/etiología , Periodo Perioperatorio , Suplementos DietéticosRESUMEN
Osteosarcoma (OS) is the most common primary malignant bone tumor in pediatric and adolescent patients. The calcyclin-binding protein/Siah-1-interacting protein (CacyBP/SIP) performs an essential function in cell proliferation and apoptosis. The present study investigated the effect of CacyBP/SIP in OS cell proliferation and apoptosis. CacyBP/SIP mRNA expression levels were evaluated in four OS cell lines by quantitative PCR. CacyBP/SIP expression was downregulated in Saos-2 cells using a lentivirus transfection system and the transfection efficiency was analyzed. The effects of CacyBP/SIP downregulation on Saos-2 cell proliferation and colony-formation ability were evaluated by MTT and colony-formation assays. The effect of CacyBP/SIP knockdown on Saos-2 cell cycle and apoptosis was analyzed by ï¬ow cytometry cell sorting. The Cancer Genome Atlas (TCGA) data was analyzed for validation. Human OS cell lines Saos-2, MG-63, HOS and U20S expressed CacyBP/SIP mRNA. CacyBP/SIP knockdown significantly inhibited cell proliferation and colony-formation ability. G1/S phase arrest was induced by CacyBP/SIP downregulation, which also resulted in the downregulation of CDK and cyclins and the upregulation of p21. In addition, CacyBP/SIP downregulation induced Saos-2 cell apoptosis mediated by Bax and Bcl-2. High expression of CacyBP/SIP was significantly associated with poor prognosis in TCGA sarcoma database. Thus, CacyBP/SIP performs important functions in the proliferation and apoptosis of human OS cells.
RESUMEN
OBJECTIVE: The purpose of this retrospective study was to evaluate the clinical and oncological results of combination treatment of short-term preoperative denosumab (the receptor activator of nuclear factor kappa-B ligand inhibitor) with surgery in unresectable or recurrent cases of giant cell tumor of the bone (GCTB). METHODS: Between 2016 and 2018, 11 eligible patients (1 man, 10 women, mean age 38.1 years) with grade 3 GCTB were treated with a combination of short-term (six doses) preoperative denosumab and surgery in a single institution. The clinical, radiological, and pathological alteration after the denosumab treatment were compared. The oncological results of the combination therapy were also recorded. Meanwhile, adverse effects or complications of denosumab, if any, were reported. RESULTS: The median follow-up time after surgical procedure was 30 months (range 13-45 months). After 3-4 denosumab injections, pain relief was observed in all patients. In two spine patients, the neurological status improved after four doses of treatment. Intraoperatively, the margin of the tumor became clear and the intensity of the tumor increased while the blood supply around and within the lesion decreased. Within the lesion, the typically soft and loose tissue were replaced by the tough and dense fibro-osseous tissue. The mean diameter of the lesion before and after treatment was 61.55 ± 22.49 mm and 51.81 ± 21.12 mm, respectively, and the T-score was 1.02 (P = 0.32). Variable calcification was observed at the periphery and within the lesion. A total of three patients experienced local recurrence in this study. In the resection group, only one extremity patient had soft tissue recurrence that was treated with en-bloc excision. In the curettage group, two of three sacral tumor patients had local occurrence. Both refused re-operation and restarted the monthly denosumab injection thereafter, and the lesions remained stable at the final follow up. Finally, no adverse effects or complications related to denosumab treatment were found. CONCLUSION: For the unresectable or recurrent GCTB cases, short-term (six doses) preoperative use of denosumab improved clinical symptoms, decreased the tumor size, and increased the tumor density. The changes in tumors, in turn, simplified the tumor removal manipulation and, subsequently, decreased the local recurrence for the resection surgery. For the curettage, the denosumab-induced changes had mixed impacts, and shorter term (fewer than six doses) usage may be more appropriate. Our six-dose regime was deemed safe, while the safety of long-term use remains unknown.